-
1
-
-
4344568552
-
Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators
-
Theocharis S, Margeli A, Vielh P and Kouraklis G: Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 30: 545-554, 2004.
-
(2004)
Cancer Treat Rev
, vol.30
, pp. 545-554
-
-
Theocharis, S.1
Margeli, A.2
Vielh, P.3
Kouraklis, G.4
-
2
-
-
34249948005
-
Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer
-
Sertzing PS, Seifert M, Tilgen W and Reichrath J: Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212: 1-12, 2007.
-
(2007)
J Cell Physiol
, vol.212
, pp. 1-12
-
-
Sertzing, P.S.1
Seifert, M.2
Tilgen, W.3
Reichrath, J.4
-
3
-
-
33644954823
-
Peroxisome proliferator-activated receptor gamma in malignant diseases
-
Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58: 1-14, 2006.
-
(2006)
Crit Rev Oncol Hematol
, vol.58
, pp. 1-14
-
-
Wang, T.1
Xu, J.2
Yu, X.3
Yang, R.4
Han, Z.C.5
-
4
-
-
0037235020
-
Peroxisome proliferator-activated receptor gamma and cancers
-
Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1-9
-
-
Koeffler, H.P.1
-
5
-
-
3042815666
-
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
-
Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 5: 419-429, 2004.
-
(2004)
Lancet Oncol
, vol.5
, pp. 419-429
-
-
Grommes, C.1
Landreth, G.E.2
Heneka, M.T.3
-
6
-
-
0034540805
-
PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells
-
Elnemr A, Ohta T, Iwata K, et al: PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 17: 1157-1164, 2000.
-
(2000)
Int J Oncol
, vol.17
, pp. 1157-1164
-
-
Elnemr, A.1
Ohta, T.2
Iwata, K.3
-
7
-
-
25444511570
-
The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines
-
Radhakrishnan SK and Gartel AL: The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 4: 582-584, 2005.
-
(2005)
Cell Cycle
, vol.4
, pp. 582-584
-
-
Radhakrishnan, S.K.1
Gartel, A.L.2
-
8
-
-
0034306992
-
Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells
-
Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 60: 5558-5564, 2000.
-
(2000)
Cancer Res
, vol.60
, pp. 5558-5564
-
-
Motomura, W.1
Okumura, T.2
Takahashi, N.3
Obara, T.4
Kohgo, Y.5
-
9
-
-
0032555196
-
Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
-
Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 8806-8811
-
-
Elstner, E.1
Muller, C.2
Koshizuka, K.3
-
10
-
-
0034235142
-
Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis
-
Chattopadhyay N, Singh DP, Heese O, et al: Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 61: 67-74, 2000.
-
(2000)
J Neurosci Res
, vol.61
, pp. 67-74
-
-
Chattopadhyay, N.1
Singh, D.P.2
Heese, O.3
-
11
-
-
33749833663
-
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
-
Vignati S, Albertini V, Rinaldi A, et al: Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861, 2006.
-
(2006)
Neoplasia
, vol.8
, pp. 851-861
-
-
Vignati, S.1
Albertini, V.2
Rinaldi, A.3
-
12
-
-
20344365809
-
Therapy insight: Potential of statins for cancer chemoprevention and therapy
-
Katz MS: Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2: 82-89, 2005.
-
(2005)
Nat Clin Pract Oncol
, vol.2
, pp. 82-89
-
-
Katz, M.S.1
-
13
-
-
2542458153
-
Potential antitumor effects of statins (Review)
-
Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
-
(2003)
Int J Oncol
, vol.23
, pp. 1055-1069
-
-
Jakobisiak, M.1
Golab, J.2
-
14
-
-
30644478973
-
HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review)
-
Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005.
-
(2005)
Int J Oncol
, vol.27
, pp. 1401-1409
-
-
Fritz, G.1
-
16
-
-
34248580619
-
Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans
-
Khurana V, Bejjanki HR, Caldito G and Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288, 2007.
-
(2007)
Chest
, vol.131
, pp. 1282-1288
-
-
Khurana, V.1
Bejjanki, H.R.2
Caldito, G.3
Owens, M.W.4
-
17
-
-
33644846806
-
Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies
-
Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23: 8606-8612, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8606-8612
-
-
Bonovas, S.1
Filioussi, K.2
Tsavaris, N.3
Sitaras, N.M.4
-
18
-
-
33846604584
-
Statins and risk of cancer: A systematic review and metaanalysis
-
Browning DR and Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120: 833-843, 2007.
-
(2007)
Int J Cancer
, vol.120
, pp. 833-843
-
-
Browning, D.R.1
Martin, R.M.2
-
19
-
-
29944446607
-
Statins and cancer risk: A meta-analysis
-
Dale KM, Coleman CI, Henyan NN, Kluger J and White CM: Statins and cancer risk: a meta-analysis. JAMA 295: 74-80, 2006.
-
(2006)
JAMA
, vol.295
, pp. 74-80
-
-
Dale, K.M.1
Coleman, C.I.2
Henyan, N.N.3
Kluger, J.4
White, C.M.5
-
20
-
-
28844495629
-
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies
-
Holstein SA, Knapp HR, Clamon GH, Murry DJ and Hohl RJ: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57: 155-164, 2006.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 155-164
-
-
Holstein, S.A.1
Knapp, H.R.2
Clamon, G.H.3
Murry, D.J.4
Hohl, R.J.5
-
21
-
-
17744394863
-
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
-
Kawata S, Yamasaki E, Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001.
-
(2001)
Br J Cancer
, vol.84
, pp. 886-891
-
-
Kawata, S.1
Yamasaki, E.2
Nagase, T.3
-
22
-
-
0030010318
-
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
-
Thibault A, Samid D, Tompkins AC, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491, 1996.
-
(1996)
Clin Cancer Res
, vol.2
, pp. 483-491
-
-
Thibault, A.1
Samid, D.2
Tompkins, A.C.3
-
23
-
-
0032005580
-
Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice
-
Feleszko W, Zagozdzon R, Golab J and Jakobisiak M: Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411, 1998.
-
(1998)
Eur J Cancer
, vol.34
, pp. 406-411
-
-
Feleszko, W.1
Zagozdzon, R.2
Golab, J.3
Jakobisiak, M.4
-
24
-
-
34447282251
-
Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo
-
Issat T, Nowis D, Legat M, et al: Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int J Oncol 30: 1413-1425, 2007.
-
(2007)
Int J Oncol
, vol.30
, pp. 1413-1425
-
-
Issat, T.1
Nowis, D.2
Legat, M.3
-
25
-
-
33745074201
-
Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity
-
Nowis D, Legat M, Grzela T, et al: Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25: 3365-3374, 2006.
-
(2006)
Oncogene
, vol.25
, pp. 3365-3374
-
-
Nowis, D.1
Legat, M.2
Grzela, T.3
-
26
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
27
-
-
30444453243
-
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
-
Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY and Chuang SE: Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 118: 773-779, 2006.
-
(2006)
Int J Cancer
, vol.118
, pp. 773-779
-
-
Yao, C.J.1
Lai, G.M.2
Chan, C.F.3
Cheng, A.L.4
Yang, Y.Y.5
Chuang, S.E.6
-
28
-
-
0345687980
-
Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells
-
Motomura W, Takahashi N, Nagamine M, et al: Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108: 41-46, 2004.
-
(2004)
Int J Cancer
, vol.108
, pp. 41-46
-
-
Motomura, W.1
Takahashi, N.2
Nagamine, M.3
-
29
-
-
0035035402
-
Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines
-
Koga H, Sakisaka S, Harada M, et al: Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097, 2001.
-
(2001)
Hepatology
, vol.33
, pp. 1087-1097
-
-
Koga, H.1
Sakisaka, S.2
Harada, M.3
-
30
-
-
0034805978
-
Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators
-
Yin F, Wakino S, Liu Z, et al: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286: 916-922, 2001.
-
(2001)
Biochem Biophys Res Commun
, vol.286
, pp. 916-922
-
-
Yin, F.1
Wakino, S.2
Liu, Z.3
-
31
-
-
0036606010
-
Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells
-
Shao J, Sheng H and DuBois RN: Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 3282-3288
-
-
Shao, J.1
Sheng, H.2
DuBois, R.N.3
-
32
-
-
0035873953
-
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
-
Patel L, Pass I, Coxon P, Downes CP, Smith SA and Macphee CH: Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768, 2001,
-
(2001)
Curr Biol
, vol.11
, pp. 764-768
-
-
Patel, L.1
Pass, I.2
Coxon, P.3
Downes, C.P.4
Smith, S.A.5
Macphee, C.H.6
-
33
-
-
33144483998
-
PPAR-gamma agonist increases gefitinib's antitumor activity through PTEN expression
-
Lee SY, Hur GY, Jung KH, et al: PPAR-gamma agonist increases gefitinib's antitumor activity through PTEN expression. Lung Cancer 51: 297-301, 2006.
-
(2006)
Lung Cancer
, vol.51
, pp. 297-301
-
-
Lee, S.Y.1
Hur, G.Y.2
Jung, K.H.3
-
34
-
-
0037138434
-
Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice
-
Giermasz A, Makowski M, Kozlowska E, et al: Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97: 746-750, 2002.
-
(2002)
Int J Cancer
, vol.97
, pp. 746-750
-
-
Giermasz, A.1
Makowski, M.2
Kozlowska, E.3
-
35
-
-
0033618378
-
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
-
Laufs U, Marra D, Node K and Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274: 21926-21931, 1999.
-
(1999)
J Biol Chem
, vol.274
, pp. 21926-21931
-
-
Laufs, U.1
Marra, D.2
Node, K.3
Liao, J.K.4
-
36
-
-
0038662665
-
Inhibition of cdk2 activating phosphorylation by mevastatin
-
Ukomadu C and Dutta A: Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 278: 4840-4846, 2003.
-
(2003)
J Biol Chem
, vol.278
, pp. 4840-4846
-
-
Ukomadu, C.1
Dutta, A.2
-
37
-
-
34347369084
-
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
-
Konstantinopoulos PA, Karamouzis MV and Papavassiliou AG: Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555, 2007.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 541-555
-
-
Konstantinopoulos, P.A.1
Karamouzis, M.V.2
Papavassiliou, A.G.3
-
38
-
-
0036053466
-
Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells
-
Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N and Kohgo Y: Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res 93: 774-782, 2002.
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 774-782
-
-
Takeuchi, S.1
Okumura, T.2
Motomura, W.3
Nagamine, M.4
Takahashi, N.5
Kohgo, Y.6
-
39
-
-
0033739334
-
Lovastatin and simvastatin are modulators of the proteasome
-
Wojcik C, Bury M, Stoklosa T, et al: Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 32: 957-965, 2000.
-
(2000)
Int J Biochem Cell Biol
, vol.32
, pp. 957-965
-
-
Wojcik, C.1
Bury, M.2
Stoklosa, T.3
-
40
-
-
0036158675
-
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis
-
Kusama T, Mukai M, Iwasaki T, et al: 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317, 2002.
-
(2002)
Gastroenterology
, vol.122
, pp. 308-317
-
-
Kusama, T.1
Mukai, M.2
Iwasaki, T.3
-
41
-
-
0036771776
-
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
-
Panigrahy D, Singer S, Shen LQ, et al: PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932, 2002.
-
(2002)
J Clin Invest
, vol.110
, pp. 923-932
-
-
Panigrahy, D.1
Singer, S.2
Shen, L.Q.3
-
42
-
-
0028925366
-
Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice
-
Feleszko W, Lasek W, Golab J and Jakobisiak M: Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice. Neoplasma 42: 69-74, 1995.
-
(1995)
Neoplasma
, vol.42
, pp. 69-74
-
-
Feleszko, W.1
Lasek, W.2
Golab, J.3
Jakobisiak, M.4
-
43
-
-
84988281451
-
Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma
-
Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25, 1999.
-
(1999)
Clin Exp Metastasis
, vol.17
, pp. 19-25
-
-
Matar, P.1
Rozados, V.R.2
Binda, M.M.3
Roggero, E.A.4
Bonfil, R.D.5
Scharovsky, O.G.6
-
44
-
-
33846273797
-
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT study
-
Hanefeld M, Marx N, Pfutzner A, et al: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 49: 290-297, 2007.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 290-297
-
-
Hanefeld, M.1
Marx, N.2
Pfutzner, A.3
|